A high level of ELOVL6 (oncogene in prostate cancer) has been proposed to be a marker of poor prognosis in BC [135], which is of great interest, as patients with luminal B type tumors generally have poorer outcomes than those with luminal A types [8]. This evidence concerns the gene ELOVL6 and prostate carcinoma.